Menu Search
Equities

Inno-Gene SA

IGN:WSE

Inno-Gene SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)2.70
  • Today's Change0.05 / 1.89%
  • Shares traded5.34k
  • 1 Year change-32.50%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Inno-Gene SA's revenues fell -93.14% from 16.44m to 1.13m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 315.00k to a loss of 6.20m.
Gross margin-44.16%
Net profit margin-1,325.33%
Operating margin-565.58%
Return on assets-82.83%
Return on equity-120.00%
Return on investment-115.27%
More ▼

Cash flow in PLNView more

In 2023, Inno-Gene SA increased its cash reserves by 83.66%, or 128.00k. Cash Flow from Investing totalled 1.76m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 2.74m for operations while cash generated from financing totalled 855.00k.
Cash flow per share-1.00
Price/Cash flow per share--
Book value per share0.4535
Tangible book value per share0.4523
More ▼

Balance sheet in PLNView more

Inno-Gene SA uses little debt in its capital structure as supported by a debt to capital ratio of 1.06%.
Current ratio1.20
Quick ratio1.20
Total debt/total equity0.0107
Total debt/total capital0.0106
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.